相关实验视频
Updated: Jul 20, 2025

04:41
Knee Arthrocentesis in Adults
Published on: February 25, 2022
7.6K
阿司匹林对症状性静脉血栓塞栓症预防的比较有效性,在接受全关节形手术的患者中,是一项队列研究
Verinder Sidhu1,2,3, Helen Badge4,5, Timothy Churches4,5
1School of Clinical Medicine, UNSW Medicine and Health, UNSW Sydney, Sydney, NSW, Australia. verinder.s.sidhu@gmail.com.
BMC musculoskeletal disorders
|August 3, 2023
概括
阿司匹林可能适用于预防关节或膝关节置换手术后的静脉血栓栓塞 (VTE). 这项研究发现阿司匹林,低分子量肝素和直接口服抗凝药的结果与阿司匹林相似.
科学领域:
- 整形外科手术 整形外科手术
- 药理学 药理学是指药理学的学科.
- 血管医学 血管医学
背景情况:
- 静脉血栓塞栓症 (VTE) 是一个重要的风险后,全部 (THA) 和全膝关节整形手术 (TKA).
- 预防策略通常包括低分子量肝素 (LMWH) 和直接口服抗凝剂 (DOAC).
- 阿司匹林在THA/TKA后的VTE预防中的作用需要进一步的比较评估.
研究的目的:
- 在接受THA和TKA的患者中比较90天的症状VTE病率.
- 评估阿司匹林与LMWH或DOAC在静脉瘤预防中的疗效.
- 评估二次结果,包括重大出血,重新手术和死亡率.
主要方法:
- 一项多中心队列研究分析了1867名患者的数据.
- 预防组包括单纯的阿司匹林,单纯的LMWH,阿司匹林与LMWH,以及DOACs.
- 症状性90天VTE是主要结局,使用后勤回归分析.
主要成果:
- 整体90天VTE的发病率为2.7%,阿司匹林组的发病率最低 (1.6%).
- 在经过调整后的分析中,在预防组之间没有观察到主要或次要结果的显著差异.
- 预防持续时间<14天和VTE病史是VTE的显著预测因素.
结论:
- 在THA和TKA之后,阿司匹林似乎是VTE预防的合适选择.
- 在阿司匹林组中,未调整的静脉瘤发作率较低,这可能归因于阿司匹林在较低风险患者中的使用.
- 进一步的研究可能会澄清阿司匹林预防的最佳患者选择.
相关概念视频
Venous Thrombosis III: Interprofessional Care
10
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
10
Venous Thrombosis IV: Nursing Management
14
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
14
Anticoagulant Drugs: Low-Molecular-Weight Heparins
753
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
753
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Venous Thrombosis I: Introduction
12
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
12
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
563
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
563

